| Primary |
| Multiple Sclerosis |
40.9% |
| Relapsing-remitting Multiple Sclerosis |
26.4% |
| Drug Use For Unknown Indication |
6.4% |
| Secondary Progressive Multiple Sclerosis |
5.3% |
| Product Used For Unknown Indication |
4.4% |
| Depression |
2.4% |
| Premedication |
2.2% |
| Hypertension |
2.1% |
| Pain |
1.9% |
| Ms |
1.0% |
| Anxiety |
0.9% |
| Headache |
0.8% |
| Insomnia |
0.8% |
| Muscle Spasms |
0.8% |
| Primary Progressive Multiple Sclerosis |
0.8% |
| Osteoporosis |
0.6% |
| Migraine |
0.6% |
| Prophylaxis |
0.6% |
| Fatigue |
0.6% |
| Convulsion |
0.5% |
|
| Death |
11.6% |
| Multiple Sclerosis |
8.6% |
| Vomiting |
7.6% |
| Pyrexia |
6.7% |
| Weight Decreased |
6.2% |
| Injection Site Pain |
5.9% |
| Influenza Like Illness |
5.5% |
| Multiple Sclerosis Relapse |
5.5% |
| Pain |
5.0% |
| Injection Site Erythema |
4.6% |
| Tremor |
4.4% |
| Urinary Tract Infection |
4.0% |
| Myocardial Infarction |
3.9% |
| Weight Increased |
3.4% |
| Depression |
3.3% |
| Pain In Extremity |
3.2% |
| Injection Site Reaction |
3.0% |
| Adverse Drug Reaction |
2.9% |
| Fatigue |
2.6% |
| Vision Blurred |
2.4% |
|
| Secondary |
| Relapsing-remitting Multiple Sclerosis |
29.5% |
| Multiple Sclerosis |
27.9% |
| Secondary Progressive Multiple Sclerosis |
6.0% |
| Drug Use For Unknown Indication |
5.7% |
| Premedication |
4.6% |
| Depression |
4.2% |
| Hypertension |
3.0% |
| Pain |
2.9% |
| Product Used For Unknown Indication |
2.6% |
| Prophylaxis |
1.8% |
| Muscle Spasms |
1.6% |
| Insomnia |
1.5% |
| Headache |
1.5% |
| Anxiety |
1.4% |
| Primary Progressive Multiple Sclerosis |
1.3% |
| Convulsion |
1.0% |
| Osteoporosis |
0.9% |
| Trigeminal Neuralgia |
0.9% |
| Hypothyroidism |
0.9% |
| Fatigue |
0.8% |
|
| Vomiting |
12.7% |
| Weight Decreased |
11.4% |
| Pyrexia |
7.9% |
| Multiple Sclerosis |
6.3% |
| Urinary Tract Infection |
6.0% |
| Tremor |
5.9% |
| Pain |
5.4% |
| Muscular Weakness |
4.2% |
| Pain In Extremity |
4.2% |
| Weight Increased |
4.1% |
| Urticaria |
4.1% |
| Somnolence |
4.0% |
| Influenza Like Illness |
3.8% |
| Multiple Sclerosis Relapse |
3.5% |
| White Blood Cell Count Decreased |
3.2% |
| Nausea |
2.9% |
| Suicidal Ideation |
2.9% |
| White Blood Cell Count Increased |
2.7% |
| Injection Site Pain |
2.4% |
| Staphylococcal Infection |
2.4% |
|
| Concomitant |
| Multiple Sclerosis |
51.5% |
| Product Used For Unknown Indication |
20.0% |
| Drug Use For Unknown Indication |
5.7% |
| Pain |
3.6% |
| Gait Disturbance |
2.5% |
| Depression |
2.4% |
| Multiple Myeloma |
2.3% |
| Fatigue |
1.5% |
| Relapsing-remitting Multiple Sclerosis |
1.4% |
| Contraception |
1.1% |
| Arthritis |
0.9% |
| Convulsion |
0.9% |
| Hypertension |
0.9% |
| Muscle Spasticity |
0.8% |
| Premedication |
0.8% |
| Hypersensitivity |
0.8% |
| Hypertonic Bladder |
0.8% |
| Muscle Spasms |
0.7% |
| Osteoporosis |
0.7% |
| Smoking Cessation Therapy |
0.7% |
|
| Multiple Sclerosis Relapse |
9.6% |
| Vomiting |
7.3% |
| Death |
6.9% |
| Weight Increased |
6.9% |
| Urinary Tract Infection |
6.4% |
| Multiple Sclerosis |
6.0% |
| Drug Ineffective |
5.5% |
| Stress |
5.5% |
| Tremor |
5.5% |
| Visual Impairment |
5.5% |
| Fatigue |
4.1% |
| Headache |
4.1% |
| Nocturia |
4.1% |
| Convulsion |
3.7% |
| Weight Decreased |
3.7% |
| Pain |
3.2% |
| Paraesthesia |
3.2% |
| Thrombosis |
3.2% |
| Pulmonary Embolism |
2.8% |
| Rash |
2.8% |
|
| Interacting |
| Drug Use For Unknown Indication |
33.3% |
| Insomnia |
33.3% |
| Relapsing-remitting Multiple Sclerosis |
33.3% |
|
| Loss Of Consciousness |
100.0% |
|
